These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6278029)

  • 41. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
    Stanberry LR; Burke R; Myers MG
    J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunologic strategies for herpes vaccination.
    Hartley C
    JAMA; 2000 Feb; 283(6):746; author reply 746-7. PubMed ID: 10683052
    [No Abstract]   [Full Text] [Related]  

  • 44. Prospects for control of herpes simplex virus disease through immunization.
    Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
    Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
    Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
    J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Herpes simplex virus genital infections.
    Swenson RM
    Clin Ther; 1986; 8(2):145-54. PubMed ID: 3009018
    [No Abstract]   [Full Text] [Related]  

  • 48. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Diaz FM; Knipe DM
    Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Herpes genitalis in pregnancy].
    Jansen CA; Bennebroek Gravenhorst J
    Ned Tijdschr Geneeskd; 1982 Mar; 126(10):421-6. PubMed ID: 6280077
    [No Abstract]   [Full Text] [Related]  

  • 50. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
    Tengvall S; Josefsson A; Holmgren J; Harandi AM
    J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpes simplex virus in human genital cancer.
    zur Hausen H
    Int Rev Exp Pathol; 1983; 25():307-26. PubMed ID: 6321379
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.
    Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D
    Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2.
    Weinberg A; Rasmussen L; Merigan TC
    J Infect Dis; 1986 Jul; 154(1):134-40. PubMed ID: 3011918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy.
    Bernstein DI; Harrison CJ; Jenski LJ; Myers MG; Stanberry LR
    J Immunol; 1991 May; 146(10):3571-7. PubMed ID: 1851194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fulminant hepatic failure due to genital herpes in a healthy woman: was she healthy?
    JAMA; 1985 Dec; 254(24):3421-2. PubMed ID: 4068179
    [No Abstract]   [Full Text] [Related]  

  • 56. Nice work for everybody except the patient.
    Skinner GR
    Vaccine; 1989 Oct; 7(5):382-4. PubMed ID: 2554604
    [No Abstract]   [Full Text] [Related]  

  • 57. Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.
    Sanna PP; Williamson RA; De Logu A; Bloom FE; Burton DR
    Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6439-43. PubMed ID: 7604009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.
    Thomson TA; Hilfenhaus J; Moser H; Morahan PS
    Infect Immun; 1983 Aug; 41(2):556-62. PubMed ID: 6307874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiviral chemotherapy--a frontier for health and learning.
    Jackson GG
    Yale J Biol Med; 1982; 55(3-4):369-74. PubMed ID: 6295012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2.
    McDermott MR; Smiley JR; Leslie P; Brais J; Rudzroga HE; Bienenstock J
    J Virol; 1984 Sep; 51(3):747-53. PubMed ID: 6088797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.